Christopher R. Heery

5.3k total citations · 1 hit paper
112 papers, 3.8k citations indexed

About

Christopher R. Heery is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher R. Heery has authored 112 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 60 papers in Immunology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher R. Heery's work include Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (49 papers) and CAR-T cell therapy research (27 papers). Christopher R. Heery is often cited by papers focused on Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (49 papers) and CAR-T cell therapy research (27 papers). Christopher R. Heery collaborates with scholars based in United States, Germany and Spain. Christopher R. Heery's co-authors include James L. Gulley, Jeffrey Schlom, Ravi A. Madan, Renee N. Donahue, Caroline Jochéms, Jennifer L. Marté, Kwong Y. Tsang, Italia Grenga, Massimo Fantini and Marijo Bilušić and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Christopher R. Heery

110 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers

Christopher R. Heery

ONCOL

IMMUN

PRM

RNMI

Andrew J. Long United States

Ryan Emerson United States

Jan Delabie Norway

Alexander N. Shoushtari United States

Denise Frosina United States

Giovanna Roncador Spain

Jennifer L. Marté United States

Joseph F. Grosso United States

Stefano Ascani Italy

Douglas G. McNeel United States

Andrew J. Long United States

Christopher R. Heery

2.9k ×1.1

ONCOL

2.8k ×1.6

IMMUN

688 ×0.8

481 ×0.6

PRM

195 ×0.7

RNMI

Citations per year, relative to Christopher R. Heery Christopher R. Heery (= 1×) peers Andrew J. Long

Countries citing papers authored by Christopher R. Heery

Since Specialization

Citations

This map shows the geographic impact of Christopher R. Heery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher R. Heery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher R. Heery more than expected).

Fields of papers citing papers by Christopher R. Heery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher R. Heery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher R. Heery. The network helps show where Christopher R. Heery may publish in the future.

Co-authorship network of co-authors of Christopher R. Heery

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher R. Heery. A scholar is included among the top collaborators of Christopher R. Heery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher R. Heery. Christopher R. Heery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bailey, Stefanie R., Eric Bartee, Kyle G. Daniels, et al.. (2025). Constructing the cure: engineering the next wave of antibody and cellular immune therapies. Journal for ImmunoTherapy of Cancer. 13(8). e011761–e011761.

Martin, Tom, Noopur Raje, Jesús F. San Miguel, et al.. (2024). MM-382 iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S554–S555. 1 indexed citations

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients. Clinical Lymphoma Myeloma & Leukemia. 24. S237–S237. 2 indexed citations

Jain, Nitin, Hagop M. Kantarjian, Scott R. Solomon, et al.. (2021). Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL. Blood. 138(Supplement 1). 650–650. 14 indexed citations

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations

Gatti‐Mays, Margaret E., Julius Strauss, Renee N. Donahue, et al.. (2019). A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clinical Cancer Research. 25(16). 4933–4944. 45 indexed citations

Strauss, Julius, Christopher R. Heery, Joseph W. Kim, et al.. (2018). First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research. 25(1). 99–109. 116 indexed citations

Strauss, Julius, Christopher R. Heery, Jeffrey Schlom, et al.. (2018). Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research. 24(6). 1287–1295. 327 indexed citations breakdown →

Heery, Christopher R., Claudia Palena, Sheri McMahon, et al.. (2017). Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research. 23(22). 6833–6845. 51 indexed citations

10.

Rajan, Arun, Christopher R. Heery, Andrew L. Mammen, et al.. (2017). OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs). Journal of Thoracic Oncology. 12(1). S314–S315. 12 indexed citations

11.

Lepone, Lauren M., Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. 5(1). 3 indexed citations

12.

Farsaci, Benedetto, Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research. 4(9). 755–765. 26 indexed citations

13.

Boyerinas, Benjamin, Caroline Jochéms, Massimo Fantini, et al.. (2015). Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research. 3(10). 1148–1157. 360 indexed citations

14.

Heery, Christopher R., Myrna Rauckhorst, Jennifer L. Marté, et al.. (2015). Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research. 3(11). 1248–1256. 104 indexed citations

15.

Arkenau, Hendrik‐Tobias, Karen Kelly, Manish R. Patel, et al.. (2015). Phase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics. Annals of Oncology. 26. viii1–viii1. 1 indexed citations

16.

Schlom, Jeffrey, James W. Hodge, Claudia Palena, et al.. (2014). Therapeutic Cancer Vaccines. Advances in cancer research. 121. 67–124. 68 indexed citations

17.

Gulley, James L., Ravi A. Madan, Kwong Y. Tsang, et al.. (2013). Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunology Research. 2(2). 133–141. 101 indexed citations

18.

Madan, Ravi A., Marijo Bilušić, Christopher R. Heery, Jeffrey Schlom, & James L. Gulley. (2012). Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. Seminars in Oncology. 39(3). 296–304. 64 indexed citations

19.

Mohebtash, Mahsa, Kwong-Yok Tsang, Ravi A. Madan, et al.. (2011). A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. Clinical Cancer Research. 17(22). 7164–7173. 101 indexed citations

20.

Bilušić, Marijo, Christopher R. Heery, & Ravi A. Madan. (2011). Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine. 29(38). 6485–6497. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact